StreetAlpha.app
Home › Stocks › XENE

Xenon Pharmaceuticals Inc. (XENE)

Healthcare
$37.04
▼ −1.38%
LAST CLOSE · NOV 20

Xenon Pharmaceuticals develops investigational drugs for neurological and psychiatric conditions, led by azetukalner for epilepsy and depression. It last closed at $37.04 on Nov 20, down 1.38% on the day. The next earnings report for XENE is expected around Thu, Feb 25, 2027, after the close. For the quarter ended Sep 2026, XENE reported EPS of -$1.11 on revenue of $0. Over its last 8 reports the stock moved an average of 5.0% the session after earnings. Over the last 12 months XENE insiders bought $1.7M of stock on the open market and sold $22.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is XENE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold XENE.

Key Stats

Last 12 months
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$428.7M
EPS (diluted)
−$4.69
Free cash flow
−$357.1M
Valuation
Market cap
$3.6B
98.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$82.6M
At Sep 30
Shareholder equity
$1.1B
Shares outstanding
98.3M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $18.4M$18.4MFY2021FY2022: $9.4M$9.4MFY2022FY2023: $0$0FY2023FY2024: $0$0FY2024FY2025: $7.5M$7.5MFY2025

From XENE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · After the close
Reported EPS
-$1.11
Quarter ended Sep 2026
Year ago EPS
-$1.15
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.84Dec '24Mar 2025: -$0.83Mar '25Jun 2025: -$1.07Jun '25Sep 2025: -$1.15Sep '25Dec 2025: -$1.31Dec '25Mar 2026: -$1.17Mar '26Jun 2026: -$1.11Jun '26Sep 2026: -$1.11Sep '26Latest -$1.11
Revenue by quarter
Dec 2024: $0Dec '24Mar 2025: $7.5MMar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How XENE moved after its last 8 reports
Average move the session after a report ±5.0%
Nov 9, 2026After the close+2.3%
Aug 6, 2026After the close−1.8%
May 7, 2026After the close+0.8%
Feb 26, 2026After the close−3.8%
Nov 3, 2025After the close−4.9%
Aug 11, 2025After the close+5.5%
May 12, 2025After the close−17.4%
Feb 27, 2025After the close−3.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on XENEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on XENE
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on XENE

Technical Analysis

XENE · as of the Nov 20 close · updated each morning
Downtrend

The stock is 4% below its 20 day and 5% below its 50 day average. It is 41% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the Pivot S1 at $36.57, and the nearest resistance the Pivot at $37.27.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 4.1%/day
Key levels
$72.6652 week high+96.2%
$52.20200 day average+40.9%
$51.24100 day average+38.3%
$39.92Swing high (Oct 1)+7.8%
$39.0250 day average+5.3%
$38.5420 day average+4.0%
$37.74Pivot R1+1.9%
$37.27Pivot+0.6%
$37.04Last close
$36.57Pivot S1−1.3%
$36.07Swing low (Sep 23)−2.6%
$33.3852 week low−9.9%
Indicators
RSI (14)41.11Middle of its rangeNeutral
MACD-0.25Below its signal lineBearish
Stochastic12.3Near the bottom of its rangeOversold
ADX (14)20.8Weak trend
Williams %R-94.8Oversold below −80, overbought above −20Oversold
CCI (20)-58.9Oversold below −100, overbought above 100Neutral
Rate of change−5.4%Change over 10 sessionsBearish
ATR (14)$1.51Typical daily range, 4.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for XENE

What happened before

See how XENE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow XENE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How XENE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for XENEHow many large options trades hit XENE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

XENE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●158 buying vs 156 selling
  • ▲Held by funds +1.1 pts
  • ▼Funds holding -29
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding288317−9.1%
In funds' top 10612−50.0%
Held by funds104.1%103.0%+1.1 pts
New / increased34 / 12447 / 125−8.1%
Reduced / sold out96 / 6087 / 23+41.8%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See XENE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

XENE Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$1.7M2 buys · 2 insiders
Sold$22.0M13 sales · 6 insiders
97% of the selling was under pre-arranged trading plans.
Cluster buy: 2 insiders bought $1.7M between Sep 30 and Sep 30.
2025-12 sold $1.1M2026-01 sold $1.8M2026-03 sold $17.8M2026-06 sold $133K2026-08 sold $1.1M2026-09 bought $1.7MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 30Ian MortimerPresident & CEOBuy30,000$37.38$1.1M
Sep 30Thomas Patrick KellyCFOBuy15,000$37.32$560K
Aug 28Christopher John KenneyChief Medical OfficerSale plan7,068$60.25$426K
Aug 11Steven GannonDirectorSale10,000$64.06$641K
Jun 5Gillian CannonDirectorSale plan1,190$53.14$63K
Jun 5Gary PatouDirectorSale plan1,322$53.14$70K
Every insider buy and sale for XENE over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See XENE insider trades →

From SEC Form 4 filings by XENE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XENE is in one of them and how their past XENE trades turned out.

XENE in the AI portfolios
Loading…

XENE News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered XENE in an article yet. Here's the latest on the wider market.

XENE in the news

About Xenon Pharmaceuticals

Xenon Pharmaceuticals is a biopharmaceutical company based in Burnaby, Canada, that focuses on drugs for neurological and psychiatric conditions. Its lead investigational medicine, azetukalner, is in late-stage trials for epilepsy, major depressive disorder and bipolar depression. The company also has earlier-stage programs aimed at pain and other conditions. Its intended customers are patients with these disorders, and it may commercialize its candidates alone or with partners.

Headquarters
Burnaby
Founded
1996